Indeed, targeting BiP via specific inhibitors may represent an effective anticancer strategy [3] and an opportunity to overcome the resistance of cancer cells to treatments inducing ER stress [4], which may be the cause of incomplete tumor elimination and tumor relapse after therapies. This evidence concerns the gene HSPA5 and neoplasm.